270 related articles for article (PubMed ID: 29027638)
1. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis.
Wang Y; Xing Y; Chen L; Meng T; Li Y; Xie J; Chen L; Dong Y; Dong W
Int J Hematol; 2018 Feb; 107(2):235-243. PubMed ID: 29027638
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
3. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital.
Chan TS; Marcella SW; Gill H; Hwang YY; Kwong YL
J Med Econ; 2016; 19(1):77-83. PubMed ID: 26366612
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
[TBL] [Abstract][Full Text] [Related]
7. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
Sung AH; Marcella SW; Xie Y
J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
[TBL] [Abstract][Full Text] [Related]
8. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.
Collins CD; Ellis JJ; Kaul DR
Am J Health Syst Pharm; 2008 Dec; 65(23):2237-43. PubMed ID: 19020192
[TBL] [Abstract][Full Text] [Related]
9. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
Rely K; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
[TBL] [Abstract][Full Text] [Related]
10. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
[TBL] [Abstract][Full Text] [Related]
11. No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation.
Bertz H; Drognitz K; Lübbert M
Ann Hematol; 2014 Jan; 93(1):165-7. PubMed ID: 23949313
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Grau S; Cámara R; Jurado M; Sanz J; Aragón B; Gozalbo I
Eur J Health Econ; 2018 May; 19(4):627-636. PubMed ID: 28569350
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
Athanasakis K; Petrakis I; Kyriopoulos J
J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
de la Cámara R; Jarque I; Sanz MA; Grau S; Casado MA; Sabater FJ; Carreras E
Bone Marrow Transplant; 2010 May; 45(5):925-32. PubMed ID: 19802030
[TBL] [Abstract][Full Text] [Related]
17. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
Mauskopf J; Chirila C; Graham J; Gersten ID; Leather H; Maziarz RT; Baden LR; Bolaños-Meade J; Brown JM; Walsh TJ; Horowitz MH; Kurtzberg J; Marr KA; Wingard JR
Am J Health Syst Pharm; 2013 Sep; 70(17):1518-27. PubMed ID: 23943184
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.
Michallet M; Gangneux JP; Lafuma A; Herbrecht R; Ribaud P; Caillot D; Dupont B; Moreau P; Berger P; O'Sullivan AK
J Med Econ; 2011; 14(1):28-35. PubMed ID: 21175376
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy.
Nomura K; Kawasugi K; Morimoto T
Eur J Cancer Care (Engl); 2006 Mar; 15(1):44-50. PubMed ID: 16441676
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
